Lab
New Vision Medical Laboratories, LLC
New Vision Medical Laboratories, LLC was paid $1.45M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 8.1% of everything it billed.
33Billing provider infoNEW VISION MEDICAL LABORATORIES, LLC
LIMA, OH 45801
LIMA, OH 45801
33aNPI1679820534assigned 08/10/2012
33bProvider typeClinical Medical Laboratory
28Total paid$1.45M
24GClaims171,985
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Ohio
Rank by total paid#40 of 116
Median peer was paid$313K
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,249 | $36K | |
| 2019 | 17,254 | $151K | |
| 2020 | 24,604 | $238K | |
| 2021 | 30,110 | $282K | |
| 2022 | 33,324 | $282K | |
| 2023 | 36,539 | $271K | |
| 2024incomplete | 24,905 | $192K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.1% | 5,610 | 5,354 | $117K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.0% | 5,612 | 5,356 | $117K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 7.0% | 6,692 | 6,267 | $102K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 6.8% | 2,611 | 2,285 | $99K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 6.8% | 5,301 | 5,063 | $99K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 5.9% | 4,328 | 4,052 | $85K |
| 84443 | Thyroid stimulating hormone (TSH) | 5.5% | 9,450 | 8,535 | $80K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 5.1% | 4,235 | 2,865 | $74K |
| 80053 | Comprehensive metabolic panel | 5.1% | 13,057 | 11,600 | $74K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 15,284 | 12,959 | $64K |
| 80061 | Lipid panel | 4.2% | 8,300 | 7,511 | $61K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.6% | 3,891 | 3,474 | $52K |
75 more codes
| 87653 | 3.2% | 2,403 | $46K | |
| 36415 | Collection of venous blood by venipuncture | 3.0% | 21,959 | $43K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.7% | 1,902 | $25K |
| 84439 | 1.7% | 4,988 | $25K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.4% | 4,429 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 4,221 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 3,336 | $16K |
| 82607 | <1% | 1,803 | $13K | |
| 86803 | <1% | 1,658 | $13K | |
| 80050 | General health panel | <1% | 986 | $13K |
| 82728 | <1% | 1,705 | $12K | |
| 87077 | <1% | 2,381 | $11K | |
| 87186 | <1% | 2,187 | $10K | |
| 87081 | <1% | 2,520 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 235 | $9K |
| 82746 | <1% | 1,392 | $9K | |
| 87522 | Neg quan hep c or qual rna | <1% | 407 | $9K |
| 88342 | <1% | 204 | $8K | |
| 83550 | <1% | 1,707 | $7K | |
| 80074 | <1% | 384 | $7K | |
| 85651 | <1% | 3,240 | $7K | |
| 87070 | <1% | 1,413 | $7K | |
| 83735 | <1% | 1,904 | $7K | |
| 86140 | <1% | 2,527 | $6K | |
| 83970 | <1% | 328 | $6K | |
| 83540 | <1% | 1,921 | $6K | |
| 85027 | <1% | 1,731 | $6K | |
| 82248 | <1% | 1,726 | $5K | |
| 86038 | <1% | 623 | $4K | |
| 85610 | <1% | 1,325 | $3K | |
| 84403 | <1% | 221 | $3K | |
| 84153 | <1% | 325 | $3K | |
| 86003 | <1% | 92 | $3K | |
| 82043 | <1% | 973 | $3K | |
| 81001 | <1% | 1,665 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 217 | $3K |
| 87205 | <1% | 1,131 | $3K | |
| 80348 | <1% | 325 | $3K | |
| 87340 | <1% | 489 | $3K | |
| 83516 | <1% | 289 | $2K | |
| 87902 | <1% | 12 | $2K | |
| 82570 | <1% | 622 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 22 | $2K |
| 86160 | <1% | 275 | $2K | |
| 80076 | <1% | 280 | $1K | |
| 84702 | <1% | 155 | $1K | |
| 86592 | <1% | 540 | $1K | |
| 84156 | <1% | 634 | $1K | |
| 82784 | <1% | 186 | $1K | |
| 87147 | <1% | 293 | $822.99 | |
| 86430 | <1% | 257 | $783.38 | |
| 80081 | <1% | 16 | $648.51 | |
| 84550 | <1% | 294 | $645.68 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14 | $397.41 |
| 86376 | <1% | 40 | $293.77 | |
| 82785 | <1% | 28 | $272.14 | |
| 84144 | <1% | 23 | $270.90 | |
| 86850 | <1% | 56 | $261.87 | |
| 86762 | <1% | 35 | $228.85 | |
| 84460 | <1% | 113 | $220.45 | |
| 84402 | <1% | 12 | $206.87 | |
| 86706 | <1% | 27 | $198.96 | |
| 84270 | <1% | 14 | $166.49 | |
| 87075 | <1% | 28 | $150.76 | |
| 84450 | <1% | 78 | $149.69 | |
| 84436 | <1% | 24 | $101.76 | |
| 86200 | <1% | 14 | $98.93 | |
| 84520 | <1% | 62 | $92.66 | |
| 86900 | <1% | 56 | $79.14 | |
| 86901 | <1% | 56 | $78.52 | |
| 83690 | <1% | 16 | $49.69 | |
| 82565 | <1% | 19 | $36.54 | |
| 84100 | <1% | 17 | $33.46 | |
| 83090 | <1% | 12 | $28.12 | |
| 81003 | <1% | 12 | $16.58 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (VP REIMBURSEMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.